Renal responses in a phase 1/2 study of at-02, a novel pan-amyloid depleter ig fusion protein for the treatment of patients with AL amyloidosisGregory Bell, Ahmad Masri, Graham S. Hillis et al.|Blood|2025Cited by 2
Clinical Trial Design of AT-02 Phase 2 Open Label Extension Study in Systemic Amyloidosis PC143 (#519)Spencer Guthrie, Matthew Meldorf, Marianna Fontana et al.|Unknown|2024Cited by 0